What Is CJC-1295 No DAC + Ipamorelin Being Studied For? GH-Axis Research Overview
CJC-1295 No DAC + Ipamorelin is a research peptide blend studied in relation to GH-axis signalling, growth-hormone-releasing hormone analogue models, ghrelin receptor signalling, growth hormone pulsatility, IGF-1 pathway research and endocrine feedback models.
This blend is commonly discussed because it combines two different GH-axis research mechanisms. CJC-1295 No DAC is commonly treated in research and supplier terminology as a shorter-acting GHRH analogue or Modified GRF-style compound, while Ipamorelin is discussed as a selective growth hormone secretagogue connected to ghrelin receptor pathway research.
At Avion BioLabs, CJC-1295 No DAC + Ipamorelin is supplied strictly for laboratory, analytical and non-clinical research use only. It is not supplied for human consumption, medical use, diagnostic use, therapeutic use, cosmetic use, veterinary use, performance use, bodybuilding use, sport use, injectable use, hormone treatment or personal use.
Research-Use-Only Notice
Important: CJC-1295 No DAC + Ipamorelin is a research peptide blend. This article is educational and research-focused only. Avion BioLabs does not provide dosage guidance, injection guidance, administration guidance, hormone-treatment guidance, performance guidance, body-composition claims, recovery claims, bodybuilding claims, medical claims, therapeutic claims, sport-use guidance or human-use instructions. Any external research or regulatory context discussed below relates to published scientific, safety or anti-doping information and should not be interpreted as a claim for any Avion BioLabs product.
For product information, view CJC-1295 No DAC + Ipamorelin | UK Stock | Research Peptide Blend. For a structured compound breakdown, visit the CJC-1295 + Ipamorelin Research Profile in the Avion Research Library.
Quick Research Summary
| Compound | CJC-1295 No DAC + Ipamorelin |
| Research category | GH-axis, GHRH analogue, ghrelin receptor and endocrine signalling research |
| Primary research pathways | GHRH receptor models, growth hormone secretagogue receptor models, GH pulsatility, IGF-1 pathway research and endocrine feedback loops |
| Evidence context | CJC-1295 with DAC has published human research; CJC-1295 No DAC / Modified GRF-style research should not be treated as identical. Ipamorelin has selective GH secretagogue research, but not Avion human-use positioning. |
| Avion BioLabs product page | CJC-1295 No DAC + Ipamorelin research peptide blend |
| Use status | Research use only. Not for human consumption. |
Why CJC-1295 No DAC + Ipamorelin Has Become a Major Research Topic
CJC-1295 No DAC + Ipamorelin has become a widely searched peptide topic because it sits within the growth hormone axis, also known as the GH axis. This is a major endocrine research area involving hypothalamic signalling, pituitary output, growth hormone release, IGF-1 pathway activity and feedback regulation.
The reason this blend attracts research interest is that each compound is discussed in relation to a different signalling route. CJC-1295 No DAC is usually connected with GHRH analogue research, while Ipamorelin is connected with growth hormone secretagogue and ghrelin receptor pathway research.
That dual-pathway positioning makes the blend highly relevant for GH-axis research categories, but it also creates compliance risk. Across the internet, CJC-1295 and Ipamorelin are often presented with body-composition, anti-ageing, recovery, sport or performance claims. Avion BioLabs deliberately avoids those claims.
Avion BioLabs does not present CJC-1295 No DAC + Ipamorelin as a hormone therapy, performance product, bodybuilding product, recovery product, anti-ageing product, medicine, injectable product or consumer-use peptide. It is supplied only for suitable laboratory, analytical and non-clinical research contexts.
Evidence Snapshot: CJC-1295 No DAC + Ipamorelin Research Landscape
The table below summarises the current research and regulatory context around CJC-1295, CJC-1295 No DAC-style terminology and Ipamorelin. This is included for transparency and should not be interpreted as human-use guidance.
| Source type | Research context | Why it matters | Important limitation |
|---|---|---|---|
| CJC-1295 hGRF analogue research | Published research identifies CJC-1295 as a stable and active hGRF(1-29) analogue with extended plasma half-life | Supports CJC-1295 relevance to GHRH analogue and GH-axis research | Long-acting CJC-1295 research should not automatically be treated as equivalent to No DAC / Modified GRF-style research |
| CJC-1295 human research | Human studies have discussed CJC-1295 effects on GH and IGF-1 levels under controlled research conditions | Provides evidence that CJC-1295 has formal GH-axis research history | Clinical research context does not make Avion BioLabs material suitable for human use |
| Ipamorelin pharmacology research | Ipamorelin has been described as a selective growth hormone secretagogue with GH-releasing potency in vitro and in vivo | Supports its relevance to growth hormone secretagogue and ghrelin receptor pathway research | Preclinical and pharmacology studies do not equal approved human-use safety or efficacy |
| FDA compounding safety material | FDA material flags potential safety risks and limited available clinical data for CJC-1295, and safety concerns around Ipamorelin acetate in compounded-drug contexts | Reinforces the need for strict research-use-only positioning | Avion BioLabs does not supply CJC-1295 or Ipamorelin for compounding, administration or human use |
| Sport anti-doping context | Growth hormone releasing factors and growth hormone secretagogues are included in prohibited sport contexts | Important for avoiding sport, bodybuilding, performance or athlete-facing positioning | Avion BioLabs does not supply products for sport, performance or personal use |
Mechanism of Interest: Why the Blend Is Studied
CJC-1295 No DAC + Ipamorelin is commonly discussed as a GH-axis research blend because the two compounds are associated with different but related signalling routes. The research interest is not simply that both compounds relate to growth hormone; it is that they approach GH-axis models from different receptor systems.
1. CJC-1295 No DAC and GHRH Analogue Research
CJC-1295 No DAC is commonly discussed in relation to growth-hormone-releasing hormone, or GHRH, pathway research. GHRH is part of the hypothalamic-pituitary signalling system that influences growth hormone release.
The “No DAC” wording is important. CJC-1295 with DAC is designed for longer duration through albumin-binding behaviour, while No DAC / Modified GRF-style research is generally discussed as shorter-acting and more aligned with pulsatile GH-axis models. These should not be treated as identical in research interpretation.
2. Ipamorelin and Growth Hormone Secretagogue Research
Ipamorelin is commonly described as a selective growth hormone secretagogue. Growth hormone secretagogues are studied for their interaction with secretagogue receptor pathways, especially research connected with ghrelin receptor signalling.
This makes Ipamorelin relevant to models involving pituitary GH release, receptor selectivity and endocrine signalling. It should not be described as a performance, recovery, anti-ageing or body-composition product.
3. GH Pulsatility Research
Growth hormone release is naturally pulsatile, meaning it occurs in peaks and troughs rather than at a constant level. Researchers are interested in how GHRH analogues and growth hormone secretagogues may influence GH-axis pulse dynamics in controlled models.
GH pulsatility discussion is a research concept only. Avion BioLabs does not provide guidance on use, administration, timing, treatment or personal application.
4. IGF-1 Pathway Research
IGF-1, or insulin-like growth factor 1, is often measured in GH-axis research because it is downstream of growth hormone signalling. Published CJC-1295 research has discussed GH and IGF-1 levels under controlled conditions.
For Avion BioLabs, IGF-1 pathway discussion is included only as educational research background and does not represent a product claim.
5. Endocrine Feedback Research
The GH axis is regulated through feedback loops involving the hypothalamus, pituitary gland, liver and peripheral tissues. Blends involving a GHRH analogue and a growth hormone secretagogue are often discussed in research because they allow comparison of overlapping endocrine signalling routes.
This makes CJC-1295 No DAC + Ipamorelin relevant to GH-axis research, but it does not make it suitable for hormone treatment, performance enhancement or personal use.
Key Research Areas for CJC-1295 No DAC + Ipamorelin
GHRH Receptor Models
CJC-1295 No DAC is commonly discussed in GHRH receptor research because it is associated with growth-hormone-releasing hormone analogue activity. This makes it relevant to pituitary signalling and endocrine pathway models.
Ghrelin Receptor and GHSR Models
Ipamorelin is commonly discussed in relation to growth hormone secretagogue receptor research. This gives it a different mechanism-of-interest from GHRH analogues and makes the blend useful for comparing GH-axis signalling routes.
GH Pulsatility and Pituitary Signalling
GH-axis research often studies pulsatile release patterns and pituitary response. CJC-1295 No DAC + Ipamorelin appears in this research category because the blend combines compounds associated with GH-releasing pathway models.
IGF-1 Pathway Research
IGF-1 is frequently included in GH-axis research because it is a downstream marker connected to growth hormone signalling. The blend is therefore relevant to models studying GH and IGF-1 pathway relationships.
Endocrine Feedback Models
The GH axis is controlled by feedback signalling. Research interest includes how GHRH analogues, secretagogues and receptor activity may influence endocrine feedback in controlled laboratory or preclinical contexts.
CJC-1295 No DAC + Ipamorelin Compared With Related Avion Research Peptides
| Compound | Research pathway focus | Common research category |
|---|---|---|
| CJC-1295 No DAC + Ipamorelin | GHRH analogue, ghrelin receptor, GH pulsatility and IGF-1 pathway models | GH-axis research blend |
| Ipamorelin | Growth hormone secretagogue receptor and ghrelin receptor pathway research | GH secretagogue research |
| MOTS-C | Mitochondrial signalling, AMPK pathways and metabolic homeostasis models | Mitochondrial and metabolic research |
| NAD+ | Cellular cofactor, redox biology, mitochondrial function and energy metabolism research | Cellular energy research |
| Retatrutide | GIP, GLP-1 and glucagon receptor pathway research | Triple-receptor metabolic research |
This comparison is for research categorisation only. It is not intended to compare consumer products, recommend use, provide medical advice, imply hormone effects or suggest suitability for any individual.
Why This Blend Requires Careful Trust and Compliance Wording
CJC-1295 No DAC + Ipamorelin is one of the most compliance-sensitive peptide topics because it is often discussed online in connection with growth hormone, body composition, recovery, bodybuilding, sport performance and anti-ageing. Those are not appropriate product claims for Avion BioLabs.
A trustworthy research article should clearly separate legitimate GH-axis research interest from human-use, sport-use and performance marketing. The scientific interest is in receptor pathways, endocrine signalling, GH pulsatility and IGF-1 models — not consumer outcomes.
FDA material has flagged safety concerns around CJC-1295 and Ipamorelin in compounded-drug contexts, and anti-doping rules treat growth hormone releasing factors and growth hormone secretagogues as prohibited in sport. This reinforces why Avion BioLabs positions CJC-1295 No DAC + Ipamorelin strictly as a research-use-only material.
Why Research Buyers Look for CJC-1295 No DAC + Ipamorelin Documentation
When sourcing a GH-axis research blend, buyers should look for more than the compound names. Responsible research supply depends on traceability, product identification, storage awareness and clear non-clinical positioning.
Important checks include:
- Clear product name and blend identification
- Correct recognition of the “No DAC” distinction
- Batch-coded identification
- COA availability where applicable
- HPLC purity verification where confirmed by batch documentation
- Research-use-only labelling
- Clear storage and handling guidance
- No performance, bodybuilding, recovery or sport-use claims
- No hormone-treatment or anti-ageing claims
- No dosage, injection, administration or human-use advice
Avion BioLabs Research Standard
- Research-use-only supply
- Batch-coded product identification
- COA transparency focus where applicable
- HPLC verification where confirmed by documentation
- UK stock where available
- Clear product pages and research profiles
- Educational Research Hub and Research Library
- No human-use, dosage, injection, performance, sport-use or hormone-treatment guidance
You can view the current product here: CJC-1295 No DAC + Ipamorelin Research Peptide Blend.
Storage and Handling Considerations
CJC-1295 No DAC + Ipamorelin, like many lyophilised research peptides, should be handled carefully in an appropriate research environment. Storage and handling should follow product-specific documentation and general laboratory best practice.
Researchers should avoid unnecessary exposure to heat, light, moisture and repeated temperature changes. Reconstitution, storage and handling procedures should only be carried out by suitably competent personnel in a proper research setting.
For general guidance, read the Avion BioLabs article: Peptide Storage and Handling: General Research Guidance.
CJC-1295 No DAC + Ipamorelin and Research-Use Positioning
CJC-1295 No DAC + Ipamorelin is not positioned by Avion BioLabs as a licensed medicine, hormone therapy, anti-ageing product, bodybuilding product, recovery product, sport product, injectable product for personal use, supplement, cosmetic product or healthcare product. Any content discussing published research, regulatory context or anti-doping context is included for educational research purposes only.
Avion BioLabs supplies CJC-1295 No DAC + Ipamorelin strictly for laboratory, analytical and non-clinical research. This page should not be used as medical advice, personal-use guidance, dosage guidance, administration guidance, sport guidance, performance guidance, hormone-treatment guidance or therapeutic information.
Related Avion BioLabs Resources
CJC-1295 No DAC + Ipamorelin Resources
Related GH-Axis and Metabolic Research
Research Tools and Library Pages
External Research References
The following external references are provided for educational research context. They do not represent Avion BioLabs product claims.
- PubMed: Human Growth Hormone-Releasing Factor hGRF(1-29) Analogue Research and Identification of CJC-1295
- PubMed: Prolonged Stimulation of GH and IGF-I Secretion by CJC-1295
- PubMed: Pulsatile Secretion of Growth Hormone Persists During Continuous Stimulation by CJC-1295
- PubMed: Ipamorelin, the First Selective Growth Hormone Secretagogue
- PMC: Growth Hormone Secretagogues and Receptor Research Context
- FDA: Certain Bulk Drug Substances for Use in Compounding May Present Significant Safety Risks
- WADA: The Prohibited List
Frequently Asked Questions
What is CJC-1295 No DAC + Ipamorelin being studied for?
CJC-1295 No DAC + Ipamorelin is being studied in relation to GH-axis signalling, GHRH analogue models, ghrelin receptor pathway research, growth hormone pulsatility, IGF-1 pathway models and endocrine feedback research.
What does “No DAC” mean in CJC-1295 No DAC?
“No DAC” refers to the absence of the drug affinity complex modification associated with longer-acting CJC-1295 variants. CJC-1295 No DAC / Modified GRF-style research is generally discussed separately from CJC-1295 with DAC and should not be treated as identical.
Is Ipamorelin the same as CJC-1295?
No. Ipamorelin and CJC-1295 are different compounds. CJC-1295 No DAC is commonly discussed in relation to GHRH analogue research, while Ipamorelin is discussed as a growth hormone secretagogue connected to ghrelin receptor pathway research.
Is CJC-1295 No DAC + Ipamorelin a hormone treatment?
No. Avion BioLabs does not position CJC-1295 No DAC + Ipamorelin as a hormone treatment, medicine, injectable product, anti-ageing product, sport product, performance product, bodybuilding product or personal-use product. It is supplied strictly for laboratory, analytical and non-clinical research use only.
Is this blend suitable for sport or performance use?
No. Avion BioLabs does not supply products for sport, performance, bodybuilding, competition, recovery or personal use. Growth hormone releasing factors and growth hormone secretagogues are also relevant to prohibited sport contexts.
Does Avion BioLabs provide CJC-1295 No DAC + Ipamorelin dosage guidance?
No. Avion BioLabs does not provide dosage, injection, administration, hormone-treatment, performance, bodybuilding, sport-use or human-use guidance. Products are supplied strictly for research use only.
Where can I find the Avion BioLabs CJC-1295 No DAC + Ipamorelin product?
You can view the product page here: CJC-1295 No DAC + Ipamorelin Research Peptide Blend.
Where can I read the Avion CJC-1295 + Ipamorelin research profile?
You can read the structured Avion Research Library page here: CJC-1295 + Ipamorelin Research Profile.
Final Thoughts
CJC-1295 No DAC + Ipamorelin is a significant GH-axis research blend because it combines two related but distinct research mechanisms: GHRH analogue pathway research and growth hormone secretagogue / ghrelin receptor pathway research.
The strongest way to approach this content is with balance: explain the research interest clearly, separate CJC-1295 with DAC from No DAC / Modified GRF-style research, acknowledge Ipamorelin’s secretagogue research profile, and avoid performance, bodybuilding, hormone-treatment and human-use claims.
Avion BioLabs supplies CJC-1295 No DAC + Ipamorelin strictly for laboratory, analytical and non-clinical research use only. Not for human consumption, medical use, diagnostic use, therapeutic use, cosmetic use, veterinary use, performance use, bodybuilding use, sport use, injectable use, hormone treatment or personal use.